Michael Wu is a National Institute of Health (NIH) fellowship-trained PhD Scientist and is an expert in next-generation sequencing (NGS), analytical chemistry, aptamer technology, and bioinformatics. Dr. Wu pioneered the development of the first urine-aptamer that detects bladder cancer-associated urinary molecules. Specializing in biosensor development and translational research, he bridges the gap between physicians and scientists, integrating clinical insights with innovative research to advance precision medicine.  Dr. Wu leads the molecular and analytical chemistry efforts for the Renal Mass BioBank, shaping its mission to revolutionize RCC care.